• FirefoxInstall the new Firefox »
  •  Dow Down1.54% Nasdaq Down1.11%

    Raptor Pharmaceuticals Corp. (RPTP)

    10.88 Up 0.11(1.02%) 3:59PM EST
    - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Raptor Pharmaceuticals Corp.
    5 Hamilton Landing
    Suite 160
    Novato, CA 94949
    United States - Map
    Phone: 415-408-6200
    Fax: 415-382-8002
    Website: http://www.raptorpharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:123

    Business Summary 

    Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Raptor Pharmaceuticals Corp.

    Corporate Governance 
    Raptor Pharmaceuticals Corp.’s ISS Governance QuickScore as of Mar 1, 2015 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Ms. Julie Anne Smith , 44
    Chief Exec. Officer, Pres and Director
    Mr. Thomas E. Daley , 52
    Chief Bus. Officer
    Dr. Todd C. Zankel Ph.D., 51
    Co-Founder and Chief Scientific Officer
    Mr. Michael P. Smith , 47
    Chief Financial Officer
    Mr. Paul K. Ross ,
    Chief Compliance Officer and VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders